Up to 6.0% Placebo-Adjusted Mean Weight Loss (7.8% From Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study Phase 2 Trial in Obesity Planned for Mid-2023 SAN DIEGO, March 28, 2023 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.